Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries

BMC Cardiovascular Disorders

Peter R Hansen¹  Christian Torp-Pedersen¹  Lone Skov³  Mette Charlot¹  Jonas B Olesen¹  Gunnar H Gislason¹  Jesper Lindhardsen¹  Ole Ahlehoff² 

[1] Department of Cardiology, Copenhagen University Hospital, Gentofte, Hellerup DK-2900, Denmark;Department of Cardiology, Copenhagen University Hospital, Roskilde, Roskilde DK-4000, Denmark;Department of Dermatology, Copenhagen University Hospital, Gentofte, Hellerup DK-2900, Denmark

关键词: Prognosis;    Psoriasis;    Inflammation;    Cardiovascular disease;    Coronary revascularization;   

Others  :  1084376
DOI  :  10.1186/1471-2261-12-79

 received in 2012-02-08, accepted in 2012-09-20,  发布年份 2012

【 摘 要 】

Background

Psoriasis is an inflammatory disease associated with increased risk of coronary artery disease. However, the potential impact of psoriasis on the prognosis following percutaneous coronary revascularization (PCI) is unknown.

Methods

The study comprised the entire Danish population undergoing first-time PCI in the period 2002–09. Cox regression models, controlling for age, gender, socioeconomic status, pharmacological treatment, and comorbidity were used to assess the risk of 1) all-cause mortality and 2) a composite endpoint of death, myocardial infarction, and stroke.

Results

A total of 53,141 patients with first-time PCI in the study period were identified. Of these, 1074 had mild psoriasis and 315 had severe psoriasis. Patients with severe psoriasis, but not those with mild disease had increased risk of both endpoints compared to patients without psoriasis. The incidence rates for all-cause mortality were 30.5 (CI 29.7-31.3), 29.9 (CI 24.7-36.1), and 47.2 (CI 35.0-63.6) per 1000 patient years for patients without psoriasis, with mild psoriasis, and with severe psoriasis, respectively. Hazard ratios were 1.10 (CI 0.91-1.33) and 1.67 (CI 1.24-2.26) for mild and severe psoriasis, respectively. Patients with severe psoriasis were less likely to receive secondary prevention pharmacotherapy with betablockers, statins and platelet inhibitors.

Conclusion

This first study of the prognosis following PCI in patients with psoriasis demonstrated an increased risk of all-cause mortality and of a composite of death, myocardial infarction and stroke, respectively, in patients with severe psoriasis compared to patients without psoriasis. Further studies of this novel association are needed.

【 授权许可】

   
2012 Ahlehoff et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009, 361:496-509.
• [2]Libby P, Ridker PM, Hansson GK: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
• [3]Frostegard J: Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005, 25:1776-1785.
• [4]Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, et al.: AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008, 102:1631-1643.
• [5]Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA: Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007, 190:1-9.
• [6]Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, et al.: The risk of stroke in patients with psoriasis. J Invest Dermatol 2009, 129:2411-2418.
• [7]Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, et al.: Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296:1735-1741.
• [8]Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, et al.: Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010, 31:1000-1006.
• [9]Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J, et al.: Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011, 270:147-157.
• [10]Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, et al.: The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011, 70:929-934.
• [11]Meesters EW, Hansen H, Spronk HM, Hamulyak K, Rosing J, et al.: The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis 2007, 18:21-28.
• [12]Ahlehoff O, Gislason GH, Lindhardsen J, Olesen JB, Charlot M, et al.: Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. J Intern Med 2011, 270:237-244.
• [13]Gisondi P, Farina S, Giordano MV, Girolomoni G: (2010) Usefulness of the Framingham Risk Score in Patients With Chronic Psoriasis. Am J Cardiol 2010, 106:1754-1757.
• [14]Ahlehoff O, Gislason GH, Jorgensen CH, Lindhardsen J, Charlot M, et al.: (2011) Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012, 33:2054-2064.
• [15]Ahlehoff O, Gislason GH, Lindhardsen J, Charlot MG, Jorgensen CH, et al.: Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One 2011, 6:e18125.
• [16]Gulliver WP, Macdonald D, Gladney N, Alaghehbandan R, Rahman P, et al.: Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population. J Cutan Med Surg 2011, 15:37-47.
• [17]Park DW, Yun SC, Lee JY, Kim WJ, Kang SJ, et al.: C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009, 120:1987-1995.
• [18]Maksimowicz-McKinnon K, Selzer F, Manzi S, Kip KE, Mulukutla SR, et al.: Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute Dynamic Registry. Circ Cardiovasc Interv 2008, 1:201-208.
• [19]Desai SP, Januzzi JL, Pande AN, Pomerantsev EV, Resnic FS, et al.: Comparison of symptoms, treatment, and outcomes of coronary artery disease among rheumatoid arthritis and matched subjects undergoing percutaneous coronary intervention. Semin Arthritis Rheum 2010, 40:215-221.
• [20]Shah MA, Shah AM, Krishnan E: Poor outcomes after acute myocardial infarction in systemic lupus erythematosus. J Rheumatol 2009, 36:570-575.
• [21]Douglas KM, Pace AV, Treharne GJ, Saratzis A, Nightingale P, et al.: Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006, 65:348-353.
• [22]Sodergren A, Stegmayr B, Lundberg V, Ohman ML, Wallberg-Jonsson S: Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis 2007, 66:263-266.
• [23]Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, et al.: Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007, 157:1249-1251.
• [24]Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, et al.: Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007, 87:506-509.
• [25]Azfar RS, Gelfand JM: Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008, 20:416-422.
• [26]Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, et al.: Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008, 22:585-589.
• [27]Kaye JA, Li L, Jick SS: Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008, 159:895-902.
• [28]Kimball AB, Robinson D Jr, Wu Y, Guzzo C, Yeilding N, et al.: Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology 2008, 217:27-37.
• [29]Gladman DD, Ang M, Su L, Tom BD, Schentag CT, et al.: Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009, 68:1131-1135.
• [30]Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, et al.: Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006, 113:2906-2913.
• [31]Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, et al.: Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009, 2:155-163.
• [32]Celano CM, Huffman JC: Depression and cardiac disease: a review. Cardiol Rev 2011, 19:130-142.
• [33]McAlister FA, Oreopoulos A, Norris CM, Graham MM, Tsuyuki RT, et al.: Exploring the treatment-risk paradox in coronary disease. Arch Intern Med 2007, 167:1019-1025.
• [34]Chung CP, Oeser A, Avalos I, Raggi P, Stein CM: Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006, 15:562-569.
• [35]Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, et al.: Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36:203-209.
• [36]Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, et al.: Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008, 59:1322-1331.
• [37]Jukema JW, Verschuren JJ, Ahmed TA, Quax PH: Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 2012, 9:53-62.
• [38]von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al.: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457.
• [39]Vermeulen MJ, Tu JV, Schull MJ: ICD-10 adaptations of the Ontario acute myocardial infarction mortality prediction rules performed as well as the original versions. J Clin Epidemiol 2007, 60:971-974.
• [40]Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M: The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003, 56:124-130.
• [41]Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T: Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007, 28:150-154.